ATR and neoplasm: WES of one eyelid mBCC tumour–stroma pair identified 150 shared nonsynonymous mutations—representing 76.5% of all stromal mutations—including mutations in ATR, EPHA3 and GLI3 (Supplementary Figures S8 and S10).